November 14, 2026
Life Science Magazines About Us Contact Us
Life Science Newswire Service™ (LS)
Submit a Press Release
  • Analytical chemistry
  • Business
  • Biomanufacturing & bioprocessing
  • Biotechnology
  • Diagnostics
  • Drug development
  • More News
    • Environmental Science
    • Food & beverage
    • Forensic science
    • Healthcare
    • Hospitals
    • Lab tools
    • Materials science
    • Microbiology
    • Nanotechnology
    • Pharma & Biopharma
    • Pharmacy
    • Veterinary
    • Water Management
  • Press Releases
Reading: S&P report highlights Big Pharma’s concentration risk amid JPM deal flurry
Share
Font ResizerAa
Life Science Newswire Service™ (LS)Life Science Newswire Service™ (LS)
Search
  • Business
  • Press Releases
  • Life Science Magazines
  • Life Sciences
    • Analytical chemistry
    • Biomanufacturing & bioprocessing
    • Biotechnology
    • Diagnostics
    • Drug development
    • Environmental Science
    • Food & beverage
    • Forensic science
    • Healthcare
    • Hospitals
    • Lab tools
    • Materials science
    • Microbiology
    • Nanotechnology
    • Pharma & Biopharma
    • Pharmacy
    • Veterinary
    • Water Management
  • About Us
  • Contact Us
  • Submit a Press Release
LS Newswire Service™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC
Life Science Newswire Service™ (LS) > Blog > Life Sciences > Drug development > S&P report highlights Big Pharma’s concentration risk amid JPM deal flurry
Drug development

S&P report highlights Big Pharma’s concentration risk amid JPM deal flurry

By Newsroom
Last updated: January 11, 2026
1 Min Read
Share


Merck is an A+ credit, a global oncology powerhouse, and still, about half its 2024 pharma revenue came from a single product: Keytruda, a product whose loss of exclusivity will hit around 2028 in the U.S. S&P Global Ratings calls that kind of concentration a “material weakness.”

Merck isn’t alone. A new S&P analysis of 17 top pharmaceutical companies, released today, finds Novo Nordisk in a similar position. More than half of its revenue rides on one product (semaglutide), well above…



Source link

TAGGED:blockbuster drugsbranded pharmabusiness strengthcredit ratingsdrug pricing reformEli LillyGLP-1JPMorgan Healthcare ConferenceKeytrudaleverageM&AMerckNovo Nordiskobesity drugspatent cliffpatent expirationsPharmaceutical acquisitionsproduct concentrationR&D investmentregulatory riskrevenue concentration riskS&P Global RatingstariffsU.S. pricing risk
Share This Article
Facebook Email Copy Link Print

HOT NEWS

Hearing Conservation – Walden

Environmental Science
April 5, 2025

How SISGAIN Is Helping UAE Enterprises Reduce Operational Costs Through AI Automation

Dubai, UAE — (ARAB NEWSWIRE) — Rising operational costs often result from repetitive business activities such…

November 12, 2026

Therapeutic Electrodes Market Projected to Grow at a CAGR of 6.2% During the Forecast Period 2021-2026

  Therapeutic Electrodes Market (I-BusinessNews.Com, August 04, 2021 ) The Therapeutic Electrodes Market size was…

August 4, 2021

Breast Imaging Market to reach USD 5.4 billion by 2025, at a CAGR of 8.1%

(I-BusinessNews.Com, August 05, 2021 ) The breast imaging market is projected to grow from an…

August 5, 2021

YOU MAY ALSO LIKE

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW. This week in DDW, innovative treatments have…

Drug development
December 14, 2025

Fix clinical trial data first

In June 2025, the Food and Drug Administration rolled out Elsa, an agency-wide generative AI assistant that officials say is…

Drug development
November 30, 2025

Pharma companies set sustainability goals, but emissions are rising

The health care industry contributes an estimated 4.4% of total global emissions annually. Approximately 71% of this comes from the…

Drug development
May 17, 2026

Pfizer sues Novo Nordisk and Metsera in bidding war

Pfizer has filed two lawsuits against the metabolic-focused startup Metsera and Novo Nordisk as of Tuesday. The first suit, filed…

Drug development
November 9, 2025
Life Science Newswire Service™ (LS)

Contact Us

  • Whatsapp: +1 832-716-2363
  • Skype: Groupwebmedia
  • Telegram: Groupwebmedia

Share Us

About Us

Life Science Newswire Services (LS)™ aggregates, publishes and distributed news about the Life Science industry. In association with EmailWire, LS provides press release distribution services in the Life Science sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us.

Categories

Analytical chemistry
Business
Biomanufacturing & bioprocessing
Biotechnology
Diagnostics
Drug development
Environmental Science
Food & beverage
Forensic science
Healthcare
Hospitals
Lab tools
Materials science
Microbiology
Nanotechnology
Pharma & Biopharma
Pharmacy
Veterinary
Water Management
Life Science Magazines
Press Releases

Recent News

How SISGAIN Is Helping UAE Enterprises Reduce Operational Costs Through AI Automation
November 12, 2026
‘SEEN FROM EVERY ANGLE:’ INSIDE MICHELLE ADEPOJU’S MUCH-ANTICIPATED KÍLẸŃTÁR SS27 RUNWAY DEBUT
November 12, 2026
The Algorithmic Newsroom: How PR and Marketing Professionals are Weaponizing Technology for Press Release Distribution in the GCC
November 12, 2026
غرفة الأخبار الخوارزمية: كيف يوظّف محترفو العلاقات العامة والتسويق التكنولوجيا لتوزيع البيانات الصحفية في دول مجلس التعاون الخليجي
November 12, 2026

Life Science Magazines

A New Blueprint: Innovations in DNA Synthesis
July 7, 2026
Inside HCP Decision-Making – The 2026 Access Landscape
July 6, 2026
Checklist for Submitting to an Institutional Review Board
July 2, 2026
Unlocking the Power of Primary Care in Cronic Disease Research
July 2, 2026

LS Newswire Service™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?